Issue 83, 2018

Towards rational design of RAD51-targeting prodrugs: platinumIV–artesunate conjugates with enhanced cytotoxicity against BRCA-proficient ovarian and breast cancer cells

Abstract

Two PtIV–artesunate anticancer prodrugs that target RAD51, a crucial protein in homologous recombination mediating the sensitivity of cancer cells to DNA-damaging agents, were designed; their cytotoxicities against BRCA-proficient ovarian and breast cancer cells are significantly higher than those of cisplatin.

Graphical abstract: Towards rational design of RAD51-targeting prodrugs: platinumIV–artesunate conjugates with enhanced cytotoxicity against BRCA-proficient ovarian and breast cancer cells

Supplementary files

Article information

Article type
Communication
Submitted
13 Aug 2018
Accepted
11 Sep 2018
First published
11 Sep 2018

Chem. Commun., 2018,54, 11717-11720

Towards rational design of RAD51-targeting prodrugs: platinumIV–artesunate conjugates with enhanced cytotoxicity against BRCA-proficient ovarian and breast cancer cells

S. Zhang, H. Yuan, Y. Guo, K. Wang, X. Wang and Z. Guo, Chem. Commun., 2018, 54, 11717 DOI: 10.1039/C8CC06576D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements